Eli Lilly & Co. reported positive top-line results for abemaciclib in the Phase III MONARCH 2 clinical trial on March 20 and revealed a regulatory strategy that has it rapidly racing after competing CDK4/6 inhibitors already approved for certain breast cancer patients.
It's hard to know whether abemaciclib can overcome its third place position, but the company will seek US FDA approval...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)